Key Events This Week
28 Sep: New 52-week and all-time high of Rs.744.75 reached
28 Sep: Stock surged to upper circuit limit, closing at Rs.739.90
29 Sep: Lower circuit hit amid heavy selling, closing at Rs.705.00
1 Oct: Continued decline to Rs.684.20, down 1.60% on the day
28 September: Rally to New Highs Amid Market Weakness
Bliss GVS Pharma Ltd began the week on a strong note, surging to a new 52-week and all-time high of Rs.744.75 on 28 September 2026. The stock closed at Rs.739.90, hitting the upper circuit limit with a 5.0% gain on the day, significantly outperforming the Sensex which declined 1.60% to 34,788.97. This rally was supported by robust buying momentum, with a turnover of ₹182.23 crore and 25.17 lakh shares traded, indicating strong investor interest despite a broadly negative market backdrop.
Technically, the stock was trading above all key moving averages, signalling sustained upward momentum. Institutional investors increased their stake by 2.05% in the previous quarter, now holding 17.54%, reflecting growing confidence. The stock’s premium valuation metrics, including a price-to-book ratio of 6.3 and a PEG ratio near 2, suggest that the market is pricing in continued growth, although the company’s five-year sales growth rate remains moderate at 10.30% annually.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- - Recent Momentum qualifier
- - Stellar technical indicators
- - Large Cap fast mover
29 September: Sharp Reversal Hits Lower Circuit
The bullish momentum reversed sharply on 29 September as Bliss GVS Pharma Ltd hit its lower circuit limit amid intense selling pressure. The stock closed at Rs.705.00, down 4.58% on the day, underperforming both the Pharmaceuticals & Biotechnology sector which gained 0.02% and the Sensex which fell 0.72%. The stock opened with a gap down of 4.29% and traded in a narrow range near the lower price band, reflecting panic selling and unfilled supply overwhelming demand.
Trading volumes remained elevated at 2.38 lakh shares with a turnover of ₹16.88 crore. Delivery volumes surged dramatically by over 2300% compared to the five-day average, indicating that investors were offloading shares rather than engaging in speculative intraday trades. Despite this sharp decline, the stock remained above its key moving averages, suggesting the dip may be a short-term correction within a longer-term uptrend.
1 October: Continued Downtrend Amid Market Pressure
On 1 October, the stock continued its downward trajectory, closing at Rs.684.20, down 1.60% on the day. The Sensex also declined sharply by 0.99% to 34,221.41, reflecting persistent market weakness. Trading volumes were subdued at 13,100 shares, indicating cautious investor participation following the previous day’s volatility. The stock’s decline over the week to Rs.684.20 represents a 3.54% loss from the week’s open of Rs.709.30, slightly underperforming the Sensex’s 3.20% fall.
Curious about Bliss GVS Pharma Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | Rs.737.60 | +3.99% | 34,788.97 | -1.60% |
| 2026-09-29 | Rs.710.05 | -3.74% | 34,621.52 | -0.48% |
| 2026-09-30 | Rs.695.35 | -2.07% | 34,564.37 | -0.17% |
| 2026-10-01 | Rs.684.20 | -1.60% | 34,221.41 | -0.99% |
Key Takeaways
Strong Technical Momentum: Bliss GVS Pharma’s stock demonstrated robust technical strength early in the week, hitting new 52-week and all-time highs and trading above all major moving averages. This indicates sustained buying interest and a positive medium-term trend despite broader market weakness.
Volatility and Circuit Hits: The week’s sharp reversal with upper and lower circuit hits on consecutive days highlights the stock’s volatility and susceptibility to rapid sentiment shifts. Heavy delivery volumes on the sell-off day suggest genuine investor profit-taking rather than speculative trading.
Institutional Confidence: Increased institutional holdings and a Mojo Score of 70.0 with a Buy grade reflect confidence in the company’s fundamentals and growth prospects, supporting the stock’s resilience amid market turbulence.
Valuation Premium and Moderate Growth: The stock trades at a premium valuation with a price-to-book ratio above 6 and a PEG ratio near 2, while its five-year sales and profit growth rates remain moderate. This balance suggests investors are pricing in continued growth but should be mindful of valuation risks.
Conclusion
Bliss GVS Pharma Ltd’s week was characterised by significant price swings, with a strong rally to record highs followed by a sharp correction and lower circuit hit. While the stock outperformed the Sensex on the rally day, it ended the week down 3.54%, slightly underperforming the broader market’s 3.20% decline. The company’s solid financial position, net-debt-free status, and growing institutional interest underpin its medium-term prospects. However, the premium valuation and recent volatility warrant cautious monitoring. Investors should watch for confirmation of sustained demand and volume quality in coming sessions to assess the durability of the current trend.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
